EGFR/HER2

Cat. No.

A26002

CAS No.

930856-19-2

ERBB agonist-1

ERBB Agonist-1 is a selective agonist for the ERBB4 receptor, facilitating its dimerization and activating the associated signaling pathway with an EC50 of 10.5 μM. This compound promotes the phosphorylation of key signaling proteins, Akt and ERK1/2, while reducing collagen expression in cardiac fibroblasts. Additionally, ERBB Agonist-1 has demonstrated protective effects against H2O2-induced cardiomyocyte death and Ang II-induced hypertrophy, making it a valuable tool for researching cardiac fibrosis and cardioprotective mechanisms in preclinical models.

Cat. No.

A28843

CAS No.

2500674-05-3

Pertuzumab zuvotolimod

Synonyms: SBT6050

Pertuzumab zuvotolimod is an anti-HER2 antibody-drug conjugate (ADC) designed to target HER2-positive tumors. The combination of a humanized anti-HER2 antibody, Pertuzumab, with a TLR8 agonist payload and a linker enhances anti-tumor immune responses by activating myeloid cells and inducing T and NK cell cytolytic activity. This reagent is suitable for research focused on HER2-expressing solid tumors, providing a valuable tool for studying therapeutic strategies in this area.

Cat. No.

A28917

CAS No.

375826-84-9

CN009543V

CN009543V is an agonist of the epidermal growth factor receptor (EGFR) that promotes tyrosine phosphorylation at residues Tyr1068 and Tyr1173, leading to the activation of the MAPK/ERK signaling cascade. Additionally, CN009543V inhibits protein tyrosine phosphatase 1B (PTP-1B) activity in MDA MB468 cancer cells. This compound is applicable in cancer research, particularly in studies focusing on EGFR signaling pathways and their implications in tumor biology.